New knowledge of the mechanisms of sorafenib resistance in liver cancer

Sorafenib is an oral multikinase inhibitor that suppresses tumor cell proliferation and angiogenesis and promotes tumor cell apoptosis It was approved by the FDA for the treatment of advanced renal cell carcinoma in 2006, and as a unique target drug for advanced hepatocellular carcinoma （HCC） in 200...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Acta pharmacologica Sinica Ročník 38; číslo 5; s. 614 - 622
Hlavní autoři:	Zhu, Yan-jing, Zheng, Bo, Wang, Hong-yang, Chen, Lei
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	London Nature Publishing Group UK 01.05.2017 Nature Publishing Group
Témata:	Antineoplastic Agents - therapeutic use Biomedical and Life Sciences Biomedicine Carcinoma, Hepatocellular - drug therapy Drug Resistance, Neoplasm Epithelial-Mesenchymal Transition Humans Immunology Internal Medicine Liver cancer Liver Neoplasms - drug therapy Medical Microbiology Niacinamide - administration & dosage Niacinamide - analogs & derivatives Niacinamide - therapeutic use Pharmacology/Toxicology Phenylurea Compounds - administration & dosage Phenylurea Compounds - therapeutic use Protein Kinase Inhibitors - therapeutic use Review Vaccine individualized treatment targeted therapy drug resistance sorafenib hepatocellular carcinoma
ISSN:	1671-4083, 1745-7254, 1745-7254
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!